AbbVie’s net revenues rise 33.9% in Q2 2021
The full-year 2021 GAAP diluted EPS and adjusted diluted EPS guidance updated to $6.04 to $6.14 and $12.52 to $12.62, respectively.
Diseases
Setback for Kyowa’s Nouryant in European Parkinson’s disease market – register for free webinar
Join GlobalData on 3 August at 4pm BST for a free webinar on the evolving...
Astellas and Minovia enter deal for mitochondrial cell therapies
The alliance plans to develop treatments that can transfer healthy mitochondria to restore the tissues...
Entrance of novel therapies will drive Pompe disease market growth
PD treatment therapies are under development and the PD market will see further growth by...
Sanofi reports 12.4% sales growth in Q2 2021
The company revised the full-year 2021 business EPS guidance, increasing it by approximately 12%.
Takeda and Frazier to launch HilleVax for norovirus vaccine development
The newly launched biopharma company will gain rights to the vaccine candidate in global markets, except Japan.
Brazilian pharmaceutical drug patent extension suspended
Pharmaceutical drug patent extension is temporarily suspended in Brazil to enable new generic drugs to be produced due to the Covid-19 pandemic.
Calico and AbbVie: Google-backed partnership re-commits to anti-ageing mission
Calico entered a partnership with global biopharma AbbVie to uncover and market novel treatments for age-related diseases in 2014.
Deep Genomics raises $180m to advance drugs for genetic diseases
The proceeds will aid in extending the company’s AI Workbench and expanding its pipeline to 30 programmes.
Amgen to acquire biotech company Teneobio for up to $2.5bn
Teneobio will receive an upfront cash payment of $900m at the closing of the deal that is expected in the coming months.
Unmet needs and opportunities in HER2+ breast cancer
Approvals and label expansions for certain therapies are positioned to partially counter some of the unmet needs in the HER2+ breast cancer space.
